...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Archivio Italiano di Urologia e Andrologia >Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women
【24h】

Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women

机译：他达拉非（Tadalafil）每天一次：对中年和老年女性中女性性功能障碍（FSD）治疗方案的叙述性评论

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Female Sexual Disorders (FSD) include a complex, multidimensional, individual experience that can change as an individual age, suggesting that these problems are caused by multiple factors including psychosocial factors, personal relationships, pathologic changes caused by diseases, and pharmacologic influences. Menopause is an important time for middle aged women and postmenopausal physiological changes could have a significant role in the development of FSD. Few is still known about their correct definition and treatment. Their incidence, prevalence and risk factors are difficult to define because of a high level of overlap in the experience of problems with desire, arousal, and orgasm. Little evidences are known about the best therapeutic approach, and both non-pharmacological and pharmacological treatment options have been described. Among these, phosphodiesterase type 5 inhibitors could be an effective option for many subtypes of female sexual disorders, with an improvement in different aspects of sexual function, such as desire, arousal, orgasm and sexual satisfaction. In this paper authors reviewed what is already known about the use of these vasoactive agents, particularly tadalafil, as a treatment option for female sexual disturbances.
机译：女性性疾病（FSD）包括复杂的，多维的，可以随年龄变化的个人经历，表明这些问题是由多种因素引起的，包括社会心理因素，人际关系，疾病引起的病理变化以及药理作用。绝经是中年妇女的重要时期，绝经后的生理变化可能在FSD的发展中起重要作用。对其正确的定义和治疗方法知之甚少。他们的发生率，患病率和危险因素难以确定，因为在欲望，唤醒和性高潮问题的经验上存在高度重叠。关于最佳治疗方法的证据鲜为人知，并且已经描述了非药物治疗和药物治疗选择。其中，磷酸二酯酶5型抑制剂可能是许多女性性障碍亚型的有效选择，并且在性功能的各个方面都有所改善，例如欲望，唤醒，性高潮和性满足。在本文中，作者回顾了关于使用这些血管活性剂（尤其是他达拉非）作为治疗女性性障碍的选择的已知信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号